HRCT Score and Serum Ferritin Level Are Factors Associated to the 1-year Mortality of Acute Interstitial Lung Disease in Clinically Amyopathic Dermatomyositis Patients

Overview

Journal Clin Rheumatol

Publisher Springer

Specialty Rheumatology

Date 2015 Jan 23

PMID 25609178

Citations 26

Authors

Jing Zou

Qiang Guo

Jiachang Chi

Huawei Wu

Chunde Bao

Affiliations

Soon will be listed here.

Abstract

The aim of this study is to evaluate the factors associated to 1-year mortality in clinically amyopathic dermatomyositis (CADM) patients with acute interstitial lung disease (ILD). A single center of 37 cases of Chinese patients with CADM was reviewed retrospectively in Renji hospital. All CADM patients were diagnosed with ILD; there were 24 cases of acute interstitial pneumonia (AIP) and 13 cases of acute exacerbation of non-acute interstitial pneumonia non-AIP. The clinical features, including blood tests, chest high-resolution computed tomography (HRCT) score, and lung function, were analyzed, respectively. Neutrophil lymphocyte ratio (NLR), serum ferritin level, serum lactate dehydrogenase (LDH) level, and HRCT score were statistically significant factors on univariate analysis. Multivariate analysis revealed that the overall HRCT score (HR 1.134, 95 % confidence interval 1.009-1.275, P = 0.017) and serum ferritin level (HR 1.001, 95 % confidence interval 1.002-1.007, P = 0.010) were independently significant factors of 1-year mortality. C statistic value of HRCT score (c statistic value 0.867, P < 0.0001) and serum ferritin level (c statistic value 0.808, P = 0.002) were statistically significant in the classification of non-survivors. Patients with calcineurin inhibitor presented a better outcome than those without calcineurin inhibitor (log-rank test, P = 0.006). HRCT score and serum ferritin level are factors associated to the 1-year mortality of acute ILD in CADM patients. Calcineurin inhibitor might improve the outcome of CADM patients with acute ILD.

Citing Articles

Clinical characteristics and prognosis of amyopathic dermatomyositis patients with interstitial lung disease: insights from a retrospective cohort.

Ying Y, Wu T, Wang L, Zhang Y, Yu Y, Deng Z Orphanet J Rare Dis. 2025; 20(1):53.

PMID: 39915831 PMC: 11804100. DOI: 10.1186/s13023-025-03575-w.

An update on autoantibodies in the idiopathic inflammatory myopathies.

Allameen N, Ramos-Lisbona A, Wedderburn L, Lundberg I, Isenberg D Nat Rev Rheumatol. 2024; 21(1):46-62.

PMID: 39609638 DOI: 10.1038/s41584-024-01188-4.

Clinical Evaluation of Acute Exacerbation of Interstitial Lung Disease in a Single Tertiary Center: Perspectives before and after the Coronavirus Disease 2019 Pandemic.

Takagi R, Saraya T, Yamada S, Nakajima K, Doi K, Akizawa T J Clin Med. 2024; 13(19).

PMID: 39407792 PMC: 11477405. DOI: 10.3390/jcm13195733.

HRCT findings predict 1-year mortality in patients with acute exacerbation of idiopathic inflammatory myopathies-associated interstitial lung disease.

Zhang J, He L, Han T, Tong J, Ren J, Pu J Heliyon. 2024; 10(11):e31510.

PMID: 38841458 PMC: 11152933. DOI: 10.1016/j.heliyon.2024.e31510.

Role of Hematological Indices as Predictors of Systemic Inflammation in Dermatology.

Aiholli S, Adya K, Inamadar A Indian Dermatol Online J. 2024; 15(2):188-195.

PMID: 38550825 PMC: 10969267. DOI: 10.4103/idoj.idoj_189_23.

References

Kotani T, Makino S, Takeuchi T, Kagitani M, Shoda T, Hata A . Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis. J Rheumatol. 2007; 35(2):254-9. View

Marie I, Hachulla E, Cherin P, Dominique S, Hatron P, Hellot M . Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum. 2003; 47(6):614-22. DOI: 10.1002/art.10794. View

Sontheimer R . Clinically amyopathic dermatomyositis: what can we now tell our patients?. Arch Dermatol. 2010; 146(1):76-80. DOI: 10.1001/archdermatol.2009.323. View

Bernard G, Artigas A, Brigham K, Carlet J, Falke K, Hudson L . The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994; 149(3 Pt 1):818-24. DOI: 10.1164/ajrccm.149.3.7509706. View

Ando M, Miyazaki E, Yamasue M, Sadamura Y, Ishii T, Takenaka R . Successful treatment with tacrolimus of progressive interstitial pneumonia associated with amyopathic dermatomyositis refractory to cyclosporine. Clin Rheumatol. 2010; 29(4):443-5. DOI: 10.1007/s10067-009-1358-x. View

Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Aihara K . The prognostic value of HRCT in myositis-associated interstitial lung disease. Respir Med. 2013; 107(5):745-52. DOI: 10.1016/j.rmed.2013.01.014. View

Hansell D, Bankier A, MacMahon H, McLoud T, Muller N, Remy J . Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008; 246(3):697-722. DOI: 10.1148/radiol.2462070712. View

Gono T, Kawaguchi Y, Hara M, Masuda I, Katsumata Y, Shinozaki M . Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). 2010; 49(7):1354-60. DOI: 10.1093/rheumatology/keq073. View

Ichikado K, Suga M, Muller N, Taniguchi H, Kondoh Y, Akira M . Acute interstitial pneumonia: comparison of high-resolution computed tomography findings between survivors and nonsurvivors. Am J Respir Crit Care Med. 2002; 165(11):1551-6. DOI: 10.1164/rccm.2106157. View

10.

Lee C, Chen T, Tzen C, Lin F, Peng M, Wu C . Idiopathic inflammatory myopathy with diffuse alveolar damage. Clin Rheumatol. 2002; 21(5):391-6. DOI: 10.1007/s100670200104. View

11.

Huh J, Kim D, Lee C, Yoo B, Seo J, Kitaichi M . Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis. Respir Med. 2007; 101(8):1761-9. DOI: 10.1016/j.rmed.2007.02.017. View

12.

Kotani T, Takeuchi T, Makino S, Hata K, Yoshida S, Nagai K . Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia. Clin Rheumatol. 2011; 30(8):1021-8. DOI: 10.1007/s10067-011-1713-6. View

13.

Ichikado K, Suga M, Gushima Y, Johkoh T, Iyonaga K, Yokoyama T . Hyperoxia-induced diffuse alveolar damage in pigs: correlation between thin-section CT and histopathologic findings. Radiology. 2000; 216(2):531-8. DOI: 10.1148/radiology.216.2.r00jl05531. View

14.

Lakhanpal S, Lie J, Conn D, Martin 2nd W . Pulmonary disease in polymyositis/dermatomyositis: a clinicopathological analysis of 65 autopsy cases. Ann Rheum Dis. 1987; 46(1):23-9. PMC: 1002053. DOI: 10.1136/ard.46.1.23. View

15.

Fathi M, Lundberg I, Tornling G . Pulmonary complications of polymyositis and dermatomyositis. Semin Respir Crit Care Med. 2007; 28(4):451-8. DOI: 10.1055/s-2007-985666. View

16.

Sontheimer R . Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?. J Am Acad Dermatol. 2002; 46(4):626-36. DOI: 10.1067/mjd.2002.120621. View

17.

Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T . Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005; 52(5):1571-6. DOI: 10.1002/art.21023. View

18.

Fathi M, Lundberg I . Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol. 2005; 17(6):701-6. DOI: 10.1097/01.bor.0000179949.65895.53. View

19.

Akobeng A . Understanding diagnostic tests 3: Receiver operating characteristic curves. Acta Paediatr. 2007; 96(5):644-7. DOI: 10.1111/j.1651-2227.2006.00178.x. View

20.

Mukae H, Ishimoto H, Sakamoto N, Hara S, Kakugawa T, Nakayama S . Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest. 2009; 136(5):1341-1347. DOI: 10.1378/chest.08-2740. View